China Medical System and a WuXi Biologics industry investment fund were among the participants in the antibody therapy developer's $69.3m series A round.
China-based antibody drug developer Trinomab closed a RMB450m ($69.3m) series A round yesterday featuring pharmaceutical company China Medical System and contract drug development and manufacturing organisation WuXi Biologics, DealStreetAsia reported. GL Ventures, the venture capital branch of hedge fund manager Hillhouse Capital, led the round, which also featured state-owned enterprise group Guolian Group, while WuXi…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.